**Table 2.** The prevalence of adverse events among patients treated with PCSK9 and ANGPTL3 inhibitors.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Adverse events** | **ANGTPL3i** | | **PCSK9i** | |
|  | **Prevalence (%)** | **95% CI** | **Prevalence (%)** | **95% CI** |
| Serious TEAE | 9.091 | 4.930 to 15.04 | 12.03 | 9.302 to 18.29 |
| Gasgtroenteritis | 4.895 | 1.990 to 9.826 | 1.250 | 0.259 to 3.609 |
| Abdominal pain | 4.196 | 1.555 to 8.909 | 0.000 | 0.000 to 1.525 |
| Nausea | 6.993 | 3.404 to 12.48 | 0.000 | 0.000 to 1.525 |
| SAMS | 0.000 | 0.000 to 2.547 | 3.750 | 1.729 to 6.999 |
| Vomiting | 3.497 | 1.145 to 7.971 | 0.000 | 0.000 to 1.525 |
| Diarrhea | 4.196 | 1.555 to 8.909 | 4.583 | 2.310 to 8.053 |
| Constipacion | 0.000 | 0.000 to 2.547 | 0.000 | 0.000 to 1.525 |
| Neurologjik disorders | 2.797 | 0.767 to 7.007 | 1.250 | 0.259 to 3.609 |
| Hepatic disorders | 0.000 | 0.000 to 2.547 | 0.000 | 0.000 to 1.525 |
| Headache | 10.08 | 7.080 to 18.35 | 8.333 | 5.164 to 12.57 |
| Myoalgia | 3.497 | 1.145 to 7.971 | 3.750 | 1.729 to 6.999 |
| Sleep disorders | 0.000 | 0.000 to 2.547 | 0.000 | 0.000 to 1.525 |
| Rash/Skin disorerders | 0.000 | 0.000 to 2.547 | 0.833 | 0.101 to 2.978 |
| Influenze like disease | 4.196 | 1.555 to 8.909 | 8.750 | 5.498 to 13.06 |
| Upper respiratory tract infection | 4.196 | 1.555 to 8.909 | 10.41 | 6.855 to 14.99 |
| CK<3, <10 x ULN | 0.000 | 0.000 to 2.547 | 5.833 | 3.225 to 9.594 |
| CK>10 x ULN | 0.000 | 0.000 to 2.547 | 3.750 | 1.729 to 6.999 |
| ALT >3 x ULN | 2.098 | 0.435 to 6.008 | 2.917 | 1.181 to 5.917 |
| AST>3 x ULN | 2.098 | 0.435 to 6.008 | 2.917 | 1.181 to 5.917 |
| Discontinuation | 1.399 | 0.170 to 4.961 | 1.667 | 0.456 to 4.212 |
| Injection side effects | 0.000 | 0.000 to 2.547 | 7.500 | 4.505 to 11.59 |
| Total (fixed effects) | 2.334 | 1.837 to 2.922 | 2.775 | 2.349 to 3.253 |
| Total (random effects) | 2.334 | 1.250 to 3.744 | 2.775 | 1.475 to 4.467 |

## *Legend: AST: Aspartate transaminase; ALT: Alanine transaminase; CK: Creatine kinase; SAMS: Statin-Associated Muscle Symptoms; TEAE: Treatment-emergent adverse event.*